Enanta Pharmaceuticals (STU:9EP) Cyclically Adjusted Book per Share: €15.90 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9EP Enanta Pharmaceuticals Inc STU:9EP
58 GF Score
Price €11.50
GF Value €7.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Cyclically Adjusted Book per Share?

Enanta Pharmaceuticals STU:9EP 58 Cyclically Adjusted Book per Share is €15.90 as of Mar. 2026. GuruFocus rates STU:9EP with a GF Score™ of 58/100 and a GF Value™ of €7.57 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Enanta Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €3.470. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €15.90 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Enanta Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -4.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Enanta Pharmaceuticals was 8.00% per year. The lowest was 1.50% per year. And the median was 4.75% per year.

As of today (2026-07-16), Enanta Pharmaceuticals's current stock price is €11.50. Enanta Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €15.90. Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.72.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enanta Pharmaceuticals was 6.25. The lowest was 0.24. And the median was 0.76.


Enanta Pharmaceuticals  (STU:9EP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=11.50/15.90
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enanta Pharmaceuticals was 6.25. The lowest was 0.24. And the median was 0.76.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Enanta Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Enanta Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Cyclically Adjusted Book per Share Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.39 18.42 18.54 17.17 20.05

Enanta Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.38 15.80 20.05 16.07 15.90

STU:9EP vs PBYI, IPSC, BNTC: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


STU:9EP
58GF Score
Enanta Pharmaceuticals Inc STU:9EP
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enanta Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.47/330.2130*330.2130
=3.470

Current CPI (Mar. 2026) = 330.2130.

Enanta Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 12.577 241.018 17.231
201609 12.635 241.428 17.282
201612 13.352 241.432 18.262
201703 13.053 243.801 17.679
201706 12.162 244.955 16.395
201709 13.238 246.819 17.711
201712 14.013 246.524 18.770
201803 14.039 249.554 18.577
201806 15.957 251.989 20.910
201809 17.395 252.439 22.754
201812 19.305 251.233 25.374
201903 19.627 254.202 25.496
201906 20.149 256.143 25.976
201909 21.314 256.759 27.412
201912 21.911 256.974 28.156
202003 22.007 258.115 28.154
202006 21.262 257.797 27.235
202009 19.265 260.280 24.441
202012 18.446 260.474 23.385
202103 18.146 264.877 22.622
202106 17.160 271.696 20.856
202109 16.776 274.310 20.195
202112 16.589 278.802 19.648
202203 15.792 287.504 18.138
202206 15.432 296.311 17.198
202209 15.610 296.808 17.367
202212 13.598 296.797 15.129
202303 11.953 301.836 13.077
202306 10.425 305.109 11.283
202309 9.643 307.789 10.346
202312 8.317 306.746 8.953
202403 7.216 312.332 7.629
202406 6.531 314.175 6.864
202409 5.476 315.301 5.735
202412 5.006 315.605 5.238
202503 4.047 319.799 4.179
202506 3.215 322.561 3.291
202509 2.578 324.800 2.621
202512 3.725 324.054 3.796
202603 3.470 330.213 3.470

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €15.90 mean?
Enanta Pharmaceuticals (STU:9EP) has a Cyclically Adjusted Book per Share of €15.90 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Enanta Pharmaceuticals' current Cyclically Adjusted Book per Share is €15.90. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Cyclically Adjusted Book per Share compare to PBYI and IPSC?
Enanta Pharmaceuticals' Cyclically Adjusted Book per Share of €15.90 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Cyclically Adjusted Book per Share is €15.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.57, compared to a current price of €11.50 — trading 51.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is €15.90. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current Cyclically Adjusted Book per Share is €15.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €11.50 is trading 51.9% above its estimated GF Value™ of €7.57. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:9EP:

  • Cyclically Adjusted Book per Share: €15.90
  • GF Value™: €7.57 vs. price of €11.50 (51.9% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score

Get the complete analysis for STU:9EP

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.50
Price
€7.57
GF Value